Business Description
Devyser Diagnostics AB
ISIN : SE0016588867
Compare
Compare
Traded in other countries / regions
DVYSR.SwedenOL0.Germany IPO Date
2021-12-14Description
Devyser Diagnostics AB develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. The products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.45 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -2.28 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.01 | |||||
| Beneish M-Score | -1.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19 | |||||
| 3-Year EBITDA Growth Rate | -8.7 | |||||
| 3-Year EPS without NRI Growth Rate | -26.4 | |||||
| 3-Year FCF Growth Rate | -52.6 | |||||
| 3-Year Book Growth Rate | -8.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 33.85 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.9 | |||||
| 9-Day RSI | 43.76 | |||||
| 14-Day RSI | 47.29 | |||||
| 3-1 Month Momentum % | -5.8 | |||||
| 6-1 Month Momentum % | 10.82 | |||||
| 12-1 Month Momentum % | 42.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.48 | |||||
| Quick Ratio | 3.06 | |||||
| Cash Ratio | 1.99 | |||||
| Days Inventory | 209.07 | |||||
| Days Sales Outstanding | 65.9 | |||||
| Days Payable | 114.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.9 | |||||
| Shareholder Yield % | -1.26 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.66 | |||||
| Operating Margin % | -26.94 | |||||
| Net Margin % | -28.37 | |||||
| FCF Margin % | -57.15 | |||||
| ROE % | -16.84 | |||||
| ROA % | -12.64 | |||||
| ROIC % | -22.91 | |||||
| 3-Year ROIIC % | -16.18 | |||||
| ROC (Joel Greenblatt) % | -45.13 | |||||
| ROCE % | -12.74 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 197.22 | |||||
| PS Ratio | 9.82 | |||||
| PB Ratio | 5.93 | |||||
| Price-to-Tangible-Book | 8.39 | |||||
| EV-to-EBIT | -37.32 | |||||
| EV-to-Forward-EBIT | 142.89 | |||||
| EV-to-EBITDA | -77.24 | |||||
| EV-to-Forward-EBITDA | 46.52 | |||||
| EV-to-Revenue | 9.23 | |||||
| EV-to-Forward-Revenue | 6.83 | |||||
| EV-to-FCF | -16.17 | |||||
| Price-to-GF-Value | 0.94 | |||||
| Price-to-Net-Current-Asset-Value | 16.14 | |||||
| Price-to-Net-Cash | 106.5 | |||||
| Earnings Yield (Greenblatt) % | -2.68 | |||||
| FCF Yield % | -5.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Devyser Diagnostics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 19.064 | ||
| EPS (TTM) (€) | -0.332 | ||
| Beta | 0.89 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.68 | ||
| Volatility % | 23.32 | ||
| 14-Day RSI | 47.29 | ||
| 14-Day ATR (€) | 0.485228 | ||
| 20-Day SMA (€) | 11.0975 | ||
| 12-1 Month Momentum % | 42.18 | ||
| 52-Week Range (€) | 7.28 - 13.05 | ||
| Shares Outstanding (Mil) | 16.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Devyser Diagnostics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Devyser Diagnostics AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Devyser Diagnostics AB Frequently Asked Questions
What is Devyser Diagnostics AB(FRA:OL0)'s stock price today?
The current price of FRA:OL0 is €10.65. The 52 week high of FRA:OL0 is €13.05 and 52 week low is €7.28.
When is next earnings date of Devyser Diagnostics AB(FRA:OL0)?
The next earnings date of Devyser Diagnostics AB(FRA:OL0) is 2025-05-08 Est..
Does Devyser Diagnostics AB(FRA:OL0) pay dividends? If so, how much?
Devyser Diagnostics AB(FRA:OL0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers